Conserved serines in simian immunodeficiency virus capsid are required for virus budding  by Rue, Sarah M. et al.
www.elsevier.com/locate/yviroVirology 336 (2Conserved serines in simian immunodeficiency virus capsid are
required for virus budding
Sarah M. Ruea,b,1, Jason W. Roosa,b,1, Janice E. Clementsa,b, Sheila A. Barbera,T
aDepartment of Comparative Medicine, Johns Hopkins University School of Medicine, 733 N. Broadway, Room 831, Baltimore, MD 21205, USA
bDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Received 16 September 2004; returned to author for revision 13 November 2004; accepted 4 March 2005
Available online 6 April 2005Abstract
The simian immunodeficiency virus (SIV) capsid protein (CA), a constituent of the Pr55Gag polyprotein, is phosphorylated in virions but
not in virus-producing cells (Rue, S.M., Roos, J.W., Tarwater, P.M., Clements, J.E., Barber, S.A., 2005. Phosphorylation and proteolytic
cleavage of gag proteins in budded simian immunodeficiency virus. J. Virol. 79 (4), 2484–2492.). Using phosphoamino acid analysis of CA,
we show that serine is the primary phosphate acceptor. A series of substitution mutants of serines in the CA domain of Pr55Gag were
constructed in the infectious viral clone SIVmac239. These virus mutants were examined for defects in virus replication and virion infectivity,
release, and morphology, as well as alterations in phosphorylation of CA-containing proteins. Although the virus mutants exhibited a number
of replication defects, none of these defects could be directly attributed to aberrant CA phosphorylation. A novel defect was a block in early
budding, which was common among several virus mutants with substitutions in the CA N terminus. Together, these results indicate that
certain residues in the CA N terminus are crucial for early budding events.
D 2005 Elsevier Inc. All rights reserved.
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During the late stages of the virus lifecycle, the gag
gene of lentiviruses such as simian immunodeficiency
virus (SIV) and human immunodeficiency virus (HIV)
produces a precursor polyprotein (Pr55Gag) that is com-
prised of (from N to C terminus) the matrix (MA), capsid
(CA), p2, nucleocapsid (NC), p1, and p6 domains
(Henderson et al., 1988, 1990; Kramer et al., 1986; Mervis
et al., 1988). In HIV and SIV, Pr55Gag is directed to and
interacts with the plasma membrane via an N-terminal
myristic acid moiety and downstream basic residues in MA
(Bryant and Ratner, 1990; Freed et al., 1994; Gottlinger et
al., 1989; Pal et al., 1990; Yuan et al., 1993; Zhou et al.,
1994). Once there, Pr55Gag forms discrete sites of virion0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to the manuscript.assembly that can be visualized by electron microscopy
(EM) as flat or slightly curved patches associated with the
plasma membrane of the cell (Swanstrom and Wills,
1997). Pr55Gag subsequently initiates the budding process,
forming crescent-shaped extrusions from the plasma
membrane that are eventually released as immature virions.
While little is known about viral and cellular requirements
for the early steps of virus budding, several advances have
been made with regard to the cellular and viral factors
involved in the late steps of budding. In primate
lentiviruses, a domain in the N terminus of the p6 protein,
referred to as a blateQ or bLQ domain (Parent et al., 1995),
interacts with the host cell endocytic machinery to mediate
the final step of virus budding: the severing of the virus
from the cell (reviewed in Freed, 2002). Disruption of
these interactions by creating deletions in p6 or substitu-
tions in the L domain causes a budding defect in which
virions remain tethered to the plasma membrane by a thin
stalk, although this phenotype may be somewhat cell-type005) 37–50
S.M. Rue et al. / Virology 336 (2005) 37–5038dependent (Demirov et al., 2002; Gottlinger et al., 1991;
Yu et al., 1995).
During and after virion assembly and budding, the viral
protease cleaves Pr55Gag, liberating each of its domains as
free proteins. These cleavage events enable the virion to
undergo maturation, a morphological transformation
required for virion infectivity in which free (completely
cleaved) MA remains largely associated with the lipid
membrane while free CA condenses into a conical structure
that encapsidates NC associated with the viral RNA
(Gelderblom et al., 1987; Kaplan et al., 1993; Kohl et al.,
1988; Peng et al., 1989).
The free CA protein can be divided into two structurally
and functionally distinct domains: an N-terminal domain
(residues 1–145) and a C-terminal domain (residues 151–
231) (Berthet-Colominas et al., 1999; Gamble et al., 1996,
1997; Gitti et al., 1996; Momany et al., 1996; Worthylake et
al., 1999). The N-terminal domain is important for core
formation and post-entry events (Dorfman et al., 1994;
Reicin et al., 1996, 1995), and the C-terminal domain
mediates Gag–Gag interactions during virion assembly
(Dorfman et al., 1994; Reicin et al., 1995). The C-terminal
domain contains the most highly conserved region in CA: a
group of twenty amino acids known as the major homology
region (MHR) (Patarca and Haseltine, 1985; Wills and
Craven, 1991).
Studies with HIV-1 have demonstrated that the free
(completely cleaved) CA protein is post-translationally
modified by phosphorylation (Cartier et al., 1997, 1999;
Henderson et al., 1988; Laurent et al., 1989; Mervis et al.,
1988; Muller et al., 2002; Veronese et al., 1988). Using
phosphoamino acid analysis, it has been determined that
HIV-1 CA is phosphorylated predominantly on serine
(Mervis et al., 1988). However, to our knowledge, only
the study by Cartier et al. (1999) has sought to identify the
specific site(s) of CA phosphorylation and to elucidate the
role of CA phosphorylation in the lentivirus life cycle. In
that study, three putative phosphorylation sites were
identified by testing CA phosphorylation in virus substitu-
tion mutants of CA serines in HIV pNL4-3, and phosphor-
ylation was implicated in the capsid uncoating process. We
have previously reported that two forms of the SIV CA
protein are phosphorylated in virions but not in virus-
producing cells: the free CA protein and CA as a domain in
Pr55Gag and at least one of its cleavage intermediates (Rue
et al., 2005). Furthermore, we have demonstrated that
several CA-containing Gag polyproteins are actively phos-
phorylated over time in virions (Rue et al., 2005).
Here we report that the free SIVmac239 CA protein is
phosphorylated predominantly on serine. We created viral
substitution mutants of all CA serines in the context of
SIVmac239 and tested whether these mutant viruses exhi-
bited defects in specific steps in virus replication and/
or altered phosphorylation of CA-containing proteins. The
CA substitutions caused a variety of defects at different
stages of SIV replication. Perhaps the most notable of thesewas a severe budding defect caused by the substitution
of serines (individually or in pairs) in a specific region of the
CA N terminus with alanine. In addition, one of the viral
serine mutants, S(43)ACA SIVmac239, had a phenotype
similar to phenotypes of substitution mutants of residues
proposed to be involved in the formation of a salt bridge in
the N terminus of SIV CA (Rue et al., 2003). None of the
replication defects observed could be specifically attributed
to aberrant CA phosphorylation, but the data presented
indicate that specific residues in the CA N terminus play a
crucial role early in the budding process.Results
SIV capsid protein is phosphorylated predominantly on
serine
In our studies of the role of phosphorylation of SIV
proteins in virus replication, we consistently observed that
the free SIV capsid protein (CA) was phosphorylated in
budded SIV virions but not in virus-producing cells. In these
experiments, 293T cells transfected with infectious wild-type
SIVmac239 DNAwere in vivo-labeled with [32P]orthophos-
phate and, in parallel, [35S]methionine/cysteine. Cell and
virus lysates were immunoprecipitated with IgG-purified
SIV CA polyclonal antiserum, resolved by SDS–PAGE, and
subjected to phosphorimager analysis. Phosphorylated forms
of not only free CA but also Pr55Gag and several of its CA-
containing cleavage intermediates [p50, p41, and CA-p2, the
final intermediate in the cleavage process (Mervis et al.,
1988; Pettit et al., 1994; Tritch et al., 1991)] were
consistently phosphorylated to detectable levels in virions
but not in virus-producing cells in these assays (Rue et al.,
2005). In parallel experiments, phosphoamino acid analysis
was performed on tryptic peptides of 32P-labeled free CA,
which revealed that, as in HIV-1 CA (Mervis et al., 1988),
serine is the predominant phosphoamino acid in SIV CA
(Fig. 1A).
Five potential serine-containing consensus phosphoryla-
tion sites were identified within SIV CA using the
phosphorylation site prediction function of PhosphoBase
v. 2.0 (Center for Biological Sequence Analysis, http://
www.cbs.dtu.dk/databases/PhosphoBase/predict/predict.
php) (Table 1 and Fig. 1B; numbers indicate amino acid
positions within SIVmac239 CA). To investigate the
potential role of phosphorylation in the SIV life cycle,
two panels of virus substitution mutants in the context of the
infectious molecular clone SIVmac239 were constructed,
replacing the serines in all five consensus phosphorylation
sites with alanine individually or in pairs. First, a panel
consisting of the individual substitution mutants S(15)ACA,
S(161)ACA, and S(169)ACA, as well as the double substi-
tution mutants S(97,99)ACA and S(106,107)ACA, hereafter
referred to as the primary substitution mutant panel (Table
1), was constructed. Both residues in the S(97,99)CA and
Fig. 1. Free capsid protein (CA) in SIV virions is phosphorylated predominantly on serine. (A) CA protein immunoprecipitated from virus lysates derived from
293T cells transfected with wild-type SIVmac239 DNA and labeled with [32P]orthophosphate was resolved by SDS–PAGE and subjected to phosphoamino
acid analysis. Abbreviations: S, serine; T, threonine; Y, tyrosine. (B) Location of serines in SIVmac239 CA. The Pr55Gag protein sequences of SIVmac239
(accession no. AAA47632) (Kestler et al., 1990), HIV-1NL4-3 (accession no. AAK08483), and HIV-2ROD (accession no. FOLJG2) (Guyader et al., 1987) were
obtained from the National Center for Biotechnology Information protein database and aligned with ClustalW (www2.ebi.ac.uk/clustalw) using the BLOSUM
matrix. Only CA sequence is shown; numbers correspond to the position of each serine within SIVmac239 CA. Consensus phosphorylation sites containing
serine in SIV CA are boxed; asterisk indicates serine that is not in a known consensus phosphorylation site. MHR, major homology region.
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stituted in this primary panel in case substitution of an
individual serine in a pair of adjacent serines directed
phosphorylation onto the remaining serine.
To better define the importance of the individual serines
that were substituted in the S(97,99)ACA and S(106,107)ACA
virus mutants, mutants with individual alanine substitutions
at these positions were also constructed. These S(97)ACA,Table 1
Serines in consensus phosphorylation sites in the SIV capsid protein and
their predicted kinases
Capsid serine residue Potential kinase(s)a Alanine substitution
mutant panelb
S(15)CA PKC 18
S(97,99)CA CaMII, CKII, PKA 18, 28
S(106,107)CA CKI, CKII 18, 28
S(161)CA CKII 18
S(169)CA PKC 18
S(97)CA CaMII, CKII, PKA 28
S(99)CA – 28
S(106)CA CKII 28
S(107)CA CKI 28
a Abbreviations: PKC, protein kinase C; CaMII, calmodulin-dependent
protein kinase II; CKII, casein kinase II; PKA, protein kinase A; CKI,
casein kinase I.
b 18, primary; 28, secondary.S(99)ACA, S(106)ACA, and S(107)ACA viral substitution
mutants, along with the S(97,99)ACA and S(106,107)ACA
double mutants, will hereafter be referred to as the secondary
mutant panel (Table 1).
Growth kinetics and infectivity of virus substitution mutants
of SIV CA
To examine the ability of the SIV CA viral substitution
mutants to replicate, CEM174 cells were transfected with
wild-type or mutant infectious viral DNA and virus-
containing cell supernatants were assayed for reverse
transcriptase (RT) activity at the indicated days post-
transfection (Fig. 2). The G(2)AMA SIVmac239 virus
mutant was included as a negative control in this assay:
the G(2)AMA substitution prevents myristoylation of
Pr55Gag, thereby abolishing virion release and virus
replication in HIV and SIV (Bryant and Ratner, 1990;
Gottlinger et al., 1989; Pal et al., 1990; Rue et al., 2003). Of
the viral substitution mutants in the primary mutant panel,
only the S(161)ACA and S(169)ACA mutants showed little
alteration in growth relative to wild-type SIV (Fig. 2A). The
S(15)ACA mutant displayed substantially delayed growth
kinetics, and the S(97,99)ACA and S(106,107)ACA mutants
and the G(2)AMA negative control did not replicate to
detectable levels. To determine which of the individual
Fig. 2. Growth kinetics of SIV CA mutants. Reverse transcriptase (RT)
activity was monitored at the indicated number of days post-transfection
in supernatants of CEM174 cells transfected with infectious wild-type or
mutant SIVmac239 DNA. (A) Growth kinetics of viruses in the primary
mutant panel. (B) Growth kinetics of viruses in the secondary mutant
panel.
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S(106,107)ACA double mutants are required for virus
replication, the viral substitution mutants in the secondary
mutant panel were tested for replication in CEM174 cells
(Fig. 2B). In this assay, the individual mutants S(97)ACA
and S(99)ACA exhibited much less severe replication defects
than the double substitution mutant S(97,99)ACA. In
contrast, like the S(106,107)ACA double substitution
mutant, the S(106)ACA and S(107)ACA single substitution
mutants failed to replicate in this assay. However, it should
be noted that in 2 of the 4 replication assays performed with
S(107)ACA SIVmac239, low levels of RT activity were
detectable at day 11 or 12 post-transfection in cultures
transfected with this mutant (data not shown). This low-
level RT activity was due to a pseudoreversion event:
sequencing of viral RNA in these cultures revealed that a
single base pair change had occurred (GCA to ACA),
effectively changing the alanine to a threonine. A single
base pair change could also have created a true revertant (an
alanine to serine change), but this pseudoreversion indicates
that threonine may also be tolerated at position 107 inSIVmac239 CA. From these experiments, we can conclude
that the serines at positions 15, 106, and 107 in SIV CA are
important for virus replication and that simultaneous
substitution of alanine for the serines at positions 97 and
99 in SIV CA abrogates replication.
The infectivity of the virus mutants was examined using
the LuSIV assay developed in our laboratory (Roos et al.,
2000). In this assay, a CEM174 cell line that is stably
transfected with a plasmid that contains luciferase under the
control of the SIV long terminal repeat (LTR) (LuSIV cells)
is infected with wild-type or mutant virus. When SIVor HIV
infects these cells, the Tat protein transactivates the LTR,
inducing expression of luciferase. Quantitation of luciferase
activity in these LuSIV cells yields a very sensitive measure
of the infectivity of lentivirus virions. The infectivity of
viruses in the primary mutant panel was first examined (Fig.
3A). The S(15)ACA and S(161)ACA substitution mutants
were at least as infectious as wild-type virus, while
S(169)ACA was only 18% as infectious as wild-type. The
reduced infectivity of S(169)ACA SIVmac239 was unex-
pected, given that this virus mutant replicated with nearly
wild-type growth kinetics based on the RT activity assay
shown in Fig. 2A. Both the growth kinetics and infectivity
data were consistently obtained in multiple replicates of
these experiments. Furthermore, nearly identical growth
kinetics data were obtained when replication of the
S(169)ACA mutant in CEM174 cells was assayed by
p27 ELISA rather than RT activity (data not shown),
indicating that the results of assays of S(169)ACA growth
kinetics are not simply due to a heightened endogenous RT
activity in this mutant. Therefore, there is likely another
property of the S(169)ACA virus mutant that compensates
for its severe infectivity defect.
The S(97,99)ACA and S(106,107)ACA double substitution
mutants were completely non-infectious. Although the
S(97)ACA and S(99)ACA single substitution mutants were
only 41% and 33% as infectious as wild-type virus,
respectively, they were considerably more infectious than
the S(97,99)ACA double substitution mutant (Fig. 3B).
Similar to the S(106,107)ACA double substitution mutant,
the S(106)ACA single substitution mutant was noninfectious.
However, the S(107)ACA single substitution mutant was
impaired in infectivity (24% of wild-type) but more
infectious than the S(106)ACA and S(106,107)ACA mutants.
Together, these data indicate that the serines at positions 97,
99, 106, 107, and 169 in SIV CA are required for optimal
virion infectivity.
Transmission electron microscopy of SIV CA substitution
mutants
We next examined the virion morphology of viruses in
both the primary and secondary substitution mutant panels.
293T cells transfected with wild-type or mutant SIVmac239
proviral DNA were fixed 24 h post-transfection and
analyzed by transmission electron microscopy (EM) (Fig.
Fig. 3. Infectivity of SIV CA mutants. LuSIV infectivity assay on 293T-
derived virus from substitution mutants in the (A) primary and (B)
secondary mutant panels. Values are fold-induction luciferase activity over
background at 48 h post-infection. Data are representative of at least 5
independent experiments and values are the means of triplicate or
quadruplicate infections.
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the wild-type SIVmac239 sample (Fig. 4A). Virions pro-
duced from the S(15)ACA, S(161)ACA, and S(169)ACA viral
substitution mutants did not display detectable morpholog-
ical differences or changes in the proportion of budding,
immature, and mature virions with respect to wild-type
virions (data not shown). In contrast, we consistently
observed multiple flat discrete regions of electron-dense
material at the plasma membrane of cells transfected with
the S(97,99)ACA double substitution mutant (Fig. 4B). In
cells transfected with this mutant, no typical immature or
mature extracellular virions were observed: only a few
particles were detected, and these were of atypical morpho-
logy but correct size (see Fig. 4B, right panel). The virion
morphology of the single substitution mutants S(97)ACA
(Fig. 4C) and S(99)ACA (Fig. 4D), however, was quite
similar to that of wild-type virus, with the exception that
there appeared to be fewer mature virions in these samples
than in the wild-type sample.
The S(106,107)ACA double substitution mutant was
morphologically similar to the S(97,99)ACA double mutant:
electron-dense material accumulated at the plasma mem-brane in discrete patches, and few, very aberrant extrac-
ellular particles were detected in this sample (Fig. 4E).
Similarly, an abundance of discrete accumulations was
detected in cells transfected with the S(106)ACA (Fig. 4F)
and S(107)ACA (Fig. 4G) single substitution mutants,
although the accumulations in the S(107)ACA mutant
sample appeared to have progressed to a later stage in
budding than those in the S(106)ACA single mutant and in
the S(106,107)ACA and S(97,99)ACA double mutants (Fig.
4G, see arrow). Aberrant extracellular particles were also
present in both the S(106)ACA and S(107)ACA samples (see
Figs. 4F and G, right panels).
Virion release and CA phosphorylation in primary
substitution mutants
In the assays performed thus far, we have found that
several of the serine substitution mutants have defects at
different steps in the virus life cycle. We next wanted to
determine whether any of these defects correlated with a
decrease in phosphorylation of CA-containing proteins. To
this end, 293T cells transfected with a GFP control vector or
wild-type or mutant infectious viral DNA were metabol-
ically labeled in parallel with [35S]met/cys and [32P]ortho-
phosphate. Gag proteins in virus and cell lysates were
immunoprecipitated with SIV CA antiserum, resolved by
SDS–PAGE, and subjected to phosphorimager analysis and
band densitometry (Figs. 5 and 6). This assay was used to
examine not only the extent of phosphorylation of CA-
containing proteins in each of the virus mutants, but also the
efficiency of virion release by each mutant. Importantly,
293T cells are not permissive to SIV replication, so the
results of these assays represent a single round of virus
production. The substitution mutants in the primary mutant
panel were examined first (Fig. 5). Pr55Gag, free CA, and
several CA-containing cleavage intermediates were detected
in both 35S-labeled virus lysates and 35S-labeled cell lysates
for all virus mutants except G(2)AMA: for this mutant, Gag
proteins were only detected in cell lysates (Fig. 5A).
Relative virion release efficiency for each of the primary
mutants was calculated from band densitometry of the gels
in Fig. 5A as described in Materials and methods (Fig. 5B).
Consistent with reported results (Rue et al., 2003), the
G(2)AMA virus mutant failed to release virus in this assay.
The S(15)ACA mutant consistently exhibited a moderate
virion release defect, releasing 68% as much virus as wild-
type. In keeping with the electron microscopy data, in which
the S(97,99)ACA and S(106,107)ACA mutants appeared to
have a defect in early budding (Fig. 4), both of these double
substitution mutants exhibited a decrease in the efficiency of
particle formation: in this assay, particle release in the
S(97,99)ACA and S(106,107)ACA virus mutants was only
38% and 36% of that of wild-type, respectively. Further-
more, it is likely that the virion release defect in these
mutants is actually underrepresented in this assay. It is
possible that large aggregates that contain portions of the
Fig. 4. Transmission electron micrographs of SIV CA mutants. 293T cells transfected with infectious wild-type or mutant viral DNA were fixed, ultra-
thin sectioned, and analyzed by transmission EM. Labeled arrows indicate virions of typical morphology: b, budding; i, immature; m, mature.
Unlabeled arrows indicate accumulations at the plasma membrane. Scale bars represent 100 nm. Data presented are representative photomicrographs of
each sample.
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released from the cell in a manner independent of virus
budding; such aggregates can be visualized by EM for both
the S(97,99)ACA and S(106,107)ACA virus mutants (see Fig.
4B for an example).
The S(106,107)ACA virus mutant appeared to have a mild
processing defect: there was consistently more of the CA-p2
intermediate than of the free CA protein in virus produced
from this mutant; this was not the case in wild-type virus
[see Fig. 5A, top panel; this observation was also confirmed
by band quantitation] (data not shown). The S(161)ACA
mutant did not exhibit a release defect, and the S(169)ACA
mutant had only a mild virion release defect, releasing 83%
as much virus as wild-type.We next investigated the phosphorylation of CA-con-
taining proteins for each member of the primary viral
substitution mutant panel (Fig. 5C). Phosphorylated
Pr55Gag, several cleavage intermediates, and free CA were
readily detectable, to varying degrees, in virus derived from
wild-type SIVmac239 and the primary virus mutants (Fig.
5C, upper panel). However, consistent with our previous
observations, no phosphorylated Gag was detected in
lysates of cells producing wild-type virus or any of the
SIV CA mutants (Fig. 5C, lower panel).
In previous studies, we have demonstrated that CA
domains in at least two Gag polyproteins (Pr55Gag and the
CA-p2 cleavage intermediate) are phosphorylated in virions
(Rue et al., 2005). Therefore, we calculated the relative
Fig. 5. Virion release and phosphorylation of CA-containing proteins in primary CA substitution mutant panel viruses. (A) Virus and cell lysates from
transfected 293T cells labeled with [35S]met/cys were immunoprecipitated with SIV CA antiserum and subjected to SDS–PAGE followed by phosphorimager
analysis. (B) Efficiency of virion release by CA substitution mutants relative to wild-type virus calculated from band densitometry of gels in panel A as
described in Materials and methods. (C) Virus and cell lysates from transfected 293T cells labeled with [32P]orthophosphate were analyzed as in panel A. (D)
Phosphorylation of CA-containing proteins in virus derived from CA substitution mutants relative to wild-type virus calculated from band densitometry of gels
in panels A and C as described in Materials and methods. Results are representative of at least two independent assays.
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Pr55Gag and CA-p2 from band densitometry of the 35S and
32P virus gels in panels A and C as described in Materials and
methods (Fig. 5D). In virus produced from the S(15)ACA,
S(97,99)ACA, and S(106,107)ACA mutants, Pr55
Gag, CA-
p2, and CA were consistently hyperphosphorylated relative
to wild-type virus. In virus produced from S(161)ACA andS(169)ACA mutants, CA and CA-p2 were phosphorylated
to approximately the same extent as in wild-type virus.
Pr55Gag was phosphorylated to a lesser extent in both
S(161)ACA and S(169)ACA virus than in wild-type, but
we cannot conclude that the CA domain of Pr55Gag is
hypophosphorylated in these mutants based on this expe-
riment because previous studies have demonstrated that
Fig. 6. Virion release and phosphorylation of CA-containing proteins in secondary CA substitution mutant panel viruses. Virus and cell lysates from
labeled transfected 293T cells were immunoprecipitated and resolved by SDS–PAGE as in Fig. 5 (see Supplemental Material Fig. 1 for gels). (A) Virion
release of viral substitution mutants relative to wild-type virus calculated from band densitometry of 35S-labeled virus and cell lysate gels as described in
Materials and methods. (B) Phosphorylation of CA-containing proteins in virus derived from CA mutants relative to wild-type virus calculated from band
densitometry of 35S- and 32P-labeled virus lysate gels as described in Materials and methods. Data shown represent the results of at least two independent
assays.
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phosphorylated as well (Rue et al., 2005). Furthermore,
the fact that CA and CA-p2 were detectably phosphory-
lated in virus derived from S(161)ACA and S(169)ACA
mutants indicates that neither of the serines at these
positions is an exclusive site for CA phosphorylation.
Virion release and CA phosphorylation in secondary
substitution mutants
The relative virion release efficiency and relative phos-
phorylation of CA-containing proteins in members of the
secondary mutant panel were examined next using the
same assay as in Fig. 5 (see Supplemental Material Fig. 1
for gels; see Fig. 6 for band quantitation data). Again, the
S(97,99)ACA double substitution mutant was severely
deficient in particle release (Fig. 6A). The S(97)ACA and
S(99)ACA single substitution mutants, however, released
virus at least as efficiently as wild-type. As in earlier assays,
the S(106,107)ACA double substitution mutant released
particles at 36% of wild-type levels. The S(106)ACA and
S(107)ACA single substitution mutants also exhibited
release defects (47% and 62% of wild-type, respectively),
although the S(107)ACA virus mutant consistently released
more particles than S(106,107)ACA or S(106)ACA.
As in primary substitution mutants, phosphorylated CA-
containing proteins were observed in virions but not in virus-
producing cells in secondary substitution mutants (see
Supplemental Material Fig. 1B). The relative phosphoryla-
tion of Pr55Gag, CA-p2, and CAwas next examined in virus
produced by the secondary mutant panel (Fig. 6B). As in
earlier experiments, all three proteins were hyperphos-
phorylated in virus derived from the S(97,99)ACA and
S(106,107)ACA mutants. The individual substitution
mutants at these positions had similar hyperphosphorylationphenotypes. These phosphorylation profiles were not due to
differences in immunoreactivity among the CA substitution
mutants, as direct analysis of 32P- and 35S-labeled virus
lysates yielded similar results (data not shown).
Growth kinetics, infectivity, and virion morphology of
S(43)ACA SIVmac239
In constructing the primary and secondary virus mutant
panels, we substituted all of the serines in consensus
phosphorylation sites in SIV CA with alanine. Since
phosphoamino acid analysis of the free CA protein present
in SIV virions indicated that CA is phosphorylated
predominantly on serine, we expected that free CA, CA-
p2, and possibly Pr55Gag [as mentioned earlier, CA is not
the only phosphorylated domain in SIV Pr55Gag (Rue et al.,
2005)] in at least one of the viral substitution mutants in the
primary and secondary panels would be less phosphorylated
than in wild-type virus, but this was not the case.
Our original mutagenesis scheme targeted serines in
consensus phosphorylation sites. Analysis of the amino acid
sequence of SIV CA revealed that a single serine, S(43)CA,
had not been substituted in either the primary or secondary
mutant panels because it was not in a known consensus
phosphorylation site according to PhosphoBase (see Fig.
1B). As it was still possible that this residue is the site of
SIV CA phosphorylation, we created an alanine substitution
mutant of this serine, S(43)ACA SIVmac239, and subjected
this mutant to assays for virus function and phosphorylation
of CA-containing proteins.
The ability of the S(43)ACA viral substitution mutant to
replicate in CEM174 cells was examined by transfection
and RT assay as for the other viral mutants. S(43)ACA
SIVmac239 did not replicate to detectable levels in this
assay (data not shown). Furthermore, when S(43)ACA virus
S.M. Rue et al. / Virology 336 (2005) 37–50 45was subjected to the LuSIV assay, we found that this mutant
was completely non-infectious (Fig. 7A). The impaired
replication of S(43)ACA SIVmac239, therefore, is at least
partially due to an infectivity defect.
We next analyzed the virion morphology of S(43)ACA
SIVmac239 by transmission EM of 293T cells transfected
with this mutant (Fig. 7B). The virion morphology of the
S(43)ACA mutant was remarkably similar to that of two SIV
CA viral substitution mutants that we have previously cha-
racterized: T(47)ACA and D(50)ACA SIVmac239 (Rue et al.,
2003). Most (if not all) of the mature virions in the
S(43)ACA sample had an acentric core morphology (core
is collapsed and juxtaposed to the viral envelope; see arrow
in Fig. 7B, left panel), and immature virions were tethered
together in chains or clusters (see Fig. 7B, right panel).
Virion release and CA phosphorylation in
S(43)ACA SIVmac239
To examine whether S(43)ACA SIVmac239 was impaired
in virion release or phosphorylation of CA-containing
proteins, 293T cells transfected with a GFP control vector,Fig. 7. Analysis of the S(43)ACA virus mutant. (A) LuSIV infectivity assay on 293T
activity over background at 48 h post-infection. Data are representative of at lea
infections. (B) Transmission EM of 293T cells transfected with S(43)ACA SIVmac2
acentric mature core morphology. (C and D) Virus and cell lysates from transfecte
were immunoprecipitated with SIV CA antiserum and subjected to SDS–PAGE an
Virion release of S(43)ACA SIVmac239 relative to wild-type virus calculated from
Materials and methods. (D) Phosphorylation of CA-containing proteins in S(43
densitometry of 35S- and 32P-labeled virus lysate gels as described in Materials awild-type SIVmac239, or S(43)ACA SIVmac239 were
labeled in parallel with 35S[met/cys] and [32P]orthophos-
phate (see Supplemental Material Fig. 2 for gels; see Figs.
7C and D for band densitometry data). Virion release for the
S(43)ACA substitution mutant relative to wild-type virus
was calculated from band densitometry of the 35S gels in
Supplemental Material Fig. 2 as described in Materials and
methods and was 74% of virion release by wild-type virus
(Fig. 7C). The extent of phosphorylation of Pr55Gag, CA-p2,
and free CA in S(43)ACA mutant virus relative to wild-type
virus was then determined from the gels in Supplemental
Material Fig. 2 as described in Materials and methods (Fig.
7D). While CA-p2 and CA in S(43)ACA virus were
phosphorylated to nearly the same extent as in wild-type
virus, the Pr55Gag protein was less phosphorylated than in
wild-type. We cannot say for certain that the CA domain of
Pr55Gag is less phosphorylated in S(43)ACA virus than in
wild-type virus, because, as previously discussed, CA is not
the only domain in Pr55Gag that can be phosphorylated.
Nevertheless, given the fact that none of the serine
substitutions created in this study prevented or greatly
decreased phosphorylation of SIV CA and CA-p2, we can-derived wild-type and S(43)ACA virus. Values are fold-induction luciferase
st two independent experiments and values are the means of quadruplicate
39. Scale bars represent 100 nm. Arrow indicates a virion with characteristic
d 293T cells labeled in parallel with [35S]met/cys and [32P]orthophosphate
d phosphorimager analysis (see Supplemental Material Fig. 2 for gels). (C)
band densitometry of 35S-labeled virus and cell lysate gels as described in
)ACA SIVmac239 virus relative to wild-type virus calculated from band
nd methods.
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not abrogate CA phosphorylation.Discussion
The virus substitution mutants created in this study
exhibited several different defects at various stages of virus
replication (see Table 2 for a summary). Importantly, analysis
of these virus mutants has led to the discovery of residues in
SIV CA that are crucial early in virus budding. Pr55Gag
molecules appear to be capable of self-assembly in sub-
stitution mutants of these residues [the S(106,107)ACA and
S(97,99)ACA double substitution mutants and the S(106)ACA
and S(107)ACA single substitution mutants], since character-
istic discrete patches of assembly are visible at the plasma
membrane by EM. Like the previously characterized late (L)
domain mutants, which have a clear defect in virion release,
particle release was compromised in S(106,107)ACA,
S(97,99)ACA, S(106)ACA, and S(107)ACA virus mutants.
However, the EM profiles of these four CA mutants are quite
different from those of L domain mutants: while budding
structures in the L domain mutants are generally visible as
immature virions connected to the plasma membrane by thin
tethers, the majority of budding structures in the four CA
mutants are visible as flat or crescent-shaped electron-dense
accumulations at the plasma membrane. This difference
strongly suggests that the defects in the S(106,107)ACA,
S(97,99)ACA, S(106)ACA, and S(107)ACA virus mutants are
manifested earlier in the budding process than the defects in
the L domain mutants. As such, S(106,107)ACA,
S(97,99)ACA, S(106)ACA, and S(107)ACA SIVmac239 will
hereafter be referred to as the early budding mutants.
The S(106)CA and S(107)CA residues are both individually
important for early budding, as individual substitutions at
these positions cause defects that are similar to those of the
S(106,107)ACA double substitution mutant. In contrast, the
S(97)CA and S(99)CA residues are not absolutely required
individually for budding or for virus replication in general.Table 2
Summary of SIV CA substitution mutant phenotypes
SIVmac239 viral clone Virion morphology
Wild-type –
S(15)ACA Normal
S(97,99)ACA PM
b accumulation, aberrant particles
S(97)ACA Normal morphology, Fewer mature
S(99)ACA Normal morphology, Fewer mature
S(106,107)ACA PM accumulation, aberrant particles
S(106)ACA PM accumulation, aberrant particles
S(107)ACA PM accumulation, aberrant particles
S(161)ACA Normal
S(169)ACA Normal
S(43)ACA Acentric mature, tethered immature
a Values are presented as a percentage relative to wild-type virus.
b PM, plasma membrane.
c S(107)ACA SIVmac239 did replicate in a few experiments, but the virus produceTaken together, these data indicate that serines 106 and 107
are crucial for intra- or inter-molecular interactions that are
important at a point in between Gag assembly and virus
budding. It is likely that the serines at positions 97 and 99
participate (albeit to a lesser extent) in these same interactions
or ones that are equally required, such that the participation of
both the S(97)CA and S(99)CA residues is optimal, but
participation of only one of these residues is sufficient for
virus replication. Notably, the serines at positions 99, 106,
and 107 are either very conserved or represented by a highly
homologous residue (specifically, threonine) in primate
lentiviruses, suggesting that this region may be globally
important for HIV and SIV budding (Kuiken et al., 2002).
The data presented here indicate that single amino acid
substitutions in the CAN terminus can be detrimental to virus
budding. Previous studies have identified other substitutions
that cause defects in virion release in HIV and SIV; most of
the substitutions made in these prior studies are believed to
interfere with CA folding (Rue et al., 2003; Srivastava et al.,
1999; von Schwedler et al., 1998). These results seem to
contradict HIV-1 studies that have shown that a proviral clone
that completely lacks the CA N terminus is still capable of
particle production; however, it has been proposed that single
amino acid substitutions that cause improper folding of CA
can be more detrimental to particle production than large
deletions in CA (Borsetti et al., 1998). As such, it is possible
that the amino acid substitutions made in the four early
budding mutants characterized in this study simply cause a
severe misfolding of CA that somehow compromises
budding. However, substitution of alanine for a glutamine
residue in the HIV-1 CA N terminus [HIV Q(95)CA] that is
not only conserved in SIV (and other retroviruses) but also
very proximal in sequence to the amino acids substituted in
the early budding mutants also causes a decrease in budding
efficiency and is proposed to interfere with the interaction of
CAwith a viral or cellular protein (Srivastava et al., 1999). As
such, we cannot at this time rule out the possibility that
the substitutionsmade in the early buddingmutants disrupt an
interaction between SIV CA and a similar factor.Growth kinetics Infectivitya Virion releasea
++++ 100% 100%
+ 99% 68%
 3%, 1% 38%, 54%
+++ 41% 119%
++ 33% 116%
 0%, 0% 36%, 36%
 1% 47%
c 24% 62%
+++ 127% 100%
+++ 18% 83%
 1% 74%
d was a pseudorevertant with a threonine at position 107 instead of a serine.
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serine substitution mutants created in this study. The
inability of the S(15)ACA virus mutant to replicate to wild-
type levels can be at least partially attributed to a defect in
virion release, but not in virion infectivity or maturation.
Interestingly, this phenotype is not typical of substitutions in
the N terminus of CA: the majority of substitutions in this
region in full-length clones of HIV-1 and SIV affect (1)
virion infectivity alone, (2) virion infectivity and matura-
tion, or (3) virion infectivity, maturation, and release (Fitzon
et al., 2000; Rue et al., 2003; Tang et al., 2001; von
Schwedler et al., 1998; Wiegers et al., 1999). Although
serine at position 15 in SIVmac239 CA is highly conserved
among HIV-1, HIV-2, and SIV strains (Kuiken et al., 2002),
the phenotype of the S(15)ACA mutant may be unique to
SIV: one study reported that a virus mutant with an alanine
substitution at the homologous position in HIV-1 does not
exhibit any defects in virus replication (Cartier et al., 1999).
The serines at positions 161 and 169 in SIVmac239 lie
within the major homology region (MHR) in the C terminus
of CA. In HIV-1, substitutions in the MHR cause virion
release and virion morphology defects (Mammano et al.,
1994). This was not true for the SIV S(161)ACA virus
substitution mutant, which was not compromised at any
specific step in the virus life cycle and replicated almost as
efficiently as wild-type virus; however, it is important to
note that the S(161)CA residue is not well conserved among
retroviruses (Kuiken et al., 2002; Mammano et al., 1994).
The other virus mutant with a substitution in the MHR,
S(169)ACA SIVmac239, displayed both a severe infectivity
defect and a mild virion release defect. Infectivity defects
have been described for MHR substitutions in a number of
different retroviruses (Alin and Goff, 1996; Craven et al.,
1995; Strambio-de-Castillia and Hunter, 1992; Willems
et al., 1997); the phenotype of the S(169)ACA virus mutant
indicates that residues in the MHR may be important for
infectivity of SIV as well.
The phenotype of the S(43)ACA virus mutant is remark-
ably similar to the phenotypes of two mutants that we have
previously characterized, T(47)ACA and D(50)ACA SIV-
mac239 (Rue et al., 2003). Like these two virus mutants,
S(43)ACA SIVmac239 does not replicate in CEM174 cells,
is non-infectious, and has a mild virion release defect.
Furthermore, the virion morphology of these mutants is
strikingly similar: all three exhibit a predominantly acentric
mature core morphology (Fig. 7B and Rue et al., 2003). In
both HIV-1 and SIV, this phenotype is typical of virus
substitution mutants of CA residues that are involved in the
formation of a salt bridge in the N terminus of CA, which is
required for proper virion maturation and virion infectivity
(Fitzon et al., 2000; Rue et al., 2003; Tang et al., 2001; von
Schwedler et al., 1998). The serine at position 43 in SIV CA
is proximal to the T(47)CA and D(50)CA residues in sequence
and, potentially, in the structure of the SIV CA protein. The
S(43)CA residue is very well conserved among primate
lentiviruses and well conserved among lentiviruses in general(Kuiken et al., 2002; Rue et al., 2003). However, virus
replication did not appear to be compromised in a substitution
mutant of the homologous residue in HIV-1, serine 44
(Cartier et al., 1999). The structure of SIV CAwill have to be
determined before conclusions can be made as to whether the
S(43)CA residue, like the T(47)CA residue, may be important
for local hydrogen bonding interactions that support or
facilitate the formation of a salt bridge in the SIV CA N
terminus.
The fact that none of the alanine substitutions at CA
serines abolished or greatly decreased phosphorylation of
CA and CA-p2 indicates that SIV CA can be phosphorylated
either multiply or alternatively on several serine residues.
Furthermore, it is possible that substitution of a serine that is
phosphorylated in wild-type CA somehow results in the
phosphorylation of an alternative serine. Although CA-
containing proteins were hyperphosphorylated in several of
the virus substitution mutants created in this study, aberrant
phosphorylation is not likely the cause of any of the mutant
phenotypes, since hyperphosphorylation is not strictly
associated with a defect in a specific step or set of steps in
the virus life cycle: the hyperphosphorylation of CA-
containing proteins is a characteristic of virus mutants that
are deficient in (1) virion release alone [S(15)ACA], (2) virion
infectivity alone [S(97)ACA, S(99)ACA], and (3) virion
release, infectivity, and particle formation [S(97,99)ACA,
S(106,107)ACA, S(106)ACA, S(107)ACA].
Most of the virus mutants in which CA-containing
proteins are hyperphosphorylated have either moderate
[S(15)ACA, S(107)ACA] or severe [S(106,107)ACA,
S(106)ACA, S(97,99)ACA] defects in virion release. Since
we have shown previously that phosphorylation of CA-
containing proteins occurs after virion release (Rue et al.,
2005), it is difficult to imagine how hyperphosphorylation
events that occur subsequent to budding could affect an early
budding step. Thus, it seems more likely that the observed
hyperphosphorylation of Pr55Gag, CA-p2, and CA in these
virus mutants is simply a downstream effect of substitutions
in specific regions of SIV CA. Our previous studies indicate
that one or more cellular kinases are incorporated into SIV
particles (Rue et al., 2005); as such, one could imagine that
substitutions in defined regions of CA could enhance the
incorporation or activity of the virion-associated kinase(s).
Although further efforts to identify the specific site(s) and
nature of CA phosphorylation are necessary to determine
whether there is an absolute requirement for this modifica-
tion in the SIV life cycle, these studies indicate that residues
in the CA N terminus are critical for early budding.Materials and methods
Plasmid construction
The previously characterized clones of the 5V (p239-
SpSp5V) and 3V (p239SpE3V) halves of the SIVmac239
S.M. Rue et al. / Virology 336 (2005) 37–5048genome (AIDS Research and Reference Reagent Program)
(Kestler et al., 1990; Regier and Desrosiers, 1990) were used
to generate full-length SIVmac239 gag mutants exactly as
described in Rue et al. (2003). The mutagenesis primers used
to create the viral mutants contained the following codon
alterations: S(15)ACA (AGC Y GCC), S(43)ACA (TCA Y
GCA), S(97)ACA (TCAYGCA), S(99)ACA (TCAYGCA),
S(106)ACA (AGT Y GCT), S(107)ACA(TCA Y GCA),
S(161)ACA (AGCYGCC), S(169)ACA, (AGTYGCT). The
viral coding region of all clones was completely sequenced.
Cell culture
Human B-cell/T-cell hybrid CEM174 cells (Salter et
al., 1985), a generous gift from Dr. James Hoxie
(University of Pennsylvania), were maintained as described
in Roos et al. (2000). LuSIV cells were cultured as
previously described (Roos et al., 2000) (these cells are
available from the AIDS Research and Reference Reagent
Program # 5460). Human embryonic kidney 293T cells
(American Type Culture Collection (ATCC), Manassas,
VA) were maintained as described in Bruett and Clements
(2001), except with 0.5 mg/ml gentamicin instead of
penicillin-streptomycin.
Metabolic labeling and immunoprecipitation
293T cells transfected with the GFP control plasmid
pEGFP-N1 (BD Biosciences Clontech, Palo Alto, CA) or
infectious viral DNA using Lipofectamine and Plus
reagents (Invitrogen Corporation, Carlsbad, CA) according
to the manufacturer’s recommendations were labeled in
parallel with [35S]met/cys or [32P]orthophosphate as
described in Rue et al. (2005), except that 0.12 mCi/ml
[35S]met/cys and 1 mCi/ml [32P]orthophosphate were used,
and cells were labeled 2 h at 37 8C. Cell and virus lysates
were then prepared and immunoprecipitated with IgG-
purified rabbit SIV CA polyclonal antiserum (HRP,
Denver, PA) exactly as in Rue et al. (2005). Immunopre-
cipitates were separated on 12.5% Tris–HCl Criterion pre-
cast gels (Bio-Rad, Hercules, CA) that were fixed and
analyzed by phosphorimager analysis and band quantita-
tion using a Typhoon 9210 Phosphorimager and Molecular
Dynamics ImageQuant version 5.2 software (Amersham
Pharmacia, Piscataway, NJ).
Virion release was calculated for each viral substitution
mutant from band densitometry data derived from 35S virus
lysate and 35S cell lysate gels (Fig. 5 and Supplemental
Material Figs. 1 and 2) by dividing the total amount of Gag
in immunoprecipitates from 35S-labeled virus lysate by the
total amount of Gag in immunoprecipitates from 35S-
labeled virus and cell lysates for each mutant. Relative
virion release efficiency (Figs. 5B, 6A, and 7C) was
then calculated for each mutant by dividing the virion
release value for the mutant by the virion release value
for wild-type virus. The phosphorylation of the CA, CA-p2, and Pr55Gag proteins in virus produced from each
viral substitution mutant relative to wild-type virus (Figs.
5D, 6B, and 7D) was calculated from band densitometry
data derived from the 35S and 32P virus lysate gels (Fig.
5 and Supplemental Figs. 1 and 2) as the band intensity
of the 32P-labeled protein divided by the band intensity
of the 35S-labeled protein (the 32P/35S ratio) in the virus
mutant, divided by the 32P/35S ratio for the protein in
wild-type virus. For instance, the phosphorylation of free
CA in the S(15)ACA virus mutant relative to the
phosphorylation of free CA in wild-type virus was
calculated as [CA 32P/35S]S(15)A/[CA
32P/35S]WT.
Phosphoamino acid analysis
Virus lysates derived from 293T cells transfected with
wild-type SIVmac239 and labeled with [32P]orthophosphate
were immunoprecipitated using SIV CA antiserum and
resolved by SDS–PAGE as described above. The 32P-
labeled free CA protein band was excised from the dried gel
and digested with trypsin, and peptides were extracted from
the gel slice as described in Shevchenko et al. (1996) and
subjected to phosphoamino acid analysis as described in
Barber et al. (1998).
Virus replication and infectivity
Virus replication assays were performed as in Rue et al.
(2003). For the production of virus stocks for use in the
LuSIV infectivity assay, SIVmac239 wild-type and mutant
infectious viral DNA was transfected into 293T cells as
described above. One day post-transfection, virus-contain-
ing cell supernatants were pelleted briefly and filtered
through a 0.45-AM syringe filter (Millipore), normalized
based on RT activity, and used to infect LuSIV cells as
previously described (Roos et al., 2000). Luciferase
activity was measured 48 h post-infection and values are
reported as the fold-induction of luciferase activity over
background.
Transmission electron microscopy
Ultra-thin section transmission electron microscopy
samples were prepared as described in Rue et al. (2003)
and analyzed by Electron Microscopy Bioservices (EMBS)
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